Is there a role for docetaxel for men with high risk prostate cancer receiving radiation and androgen deprivation therapy?

Standard of care for high risk localized prostate cancer remains radiation and long term androgen deprivation therapy. To date, there are no trials that have demonstrated an overall survival benefit with the addition of chemotherapy. Given the potential toxicity of adding chemotherapy, this should n...

NRG RTOG 0521 has now been published in JCO. I may be biased (since I am study PI) but it seems reasonable to infer a small survival advantage to adjuvant docetaxel in a quite high risk prostate cancer population receiving radiotherapy and ADT. See figure 2A in the paper. Of course, one can view the...

Since the early analysis of RTOG 0521 showed a survival advantage (http://meetinglibrary.asco.org/content/144388-156), we have been referring very high risk patients for a discussion about adjuvant chemotherapy to medical oncology.

It looks the recent update of the NCCN Guidelines has removed the footnote of offering high risk patients taxotere with adt after completion of radiation, stating more fu is needed.